SI-Bone (NASDAQ:SIBN) Releases Earnings Results, Misses Expectations By $0.10 EPS

SI-Bone (NASDAQ:SIBN) posted its quarterly earnings results on Monday. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.10), Fidelity Earnings reports. The company had revenue of $16.18 million during the quarter. SI-Bone had a negative return on equity of 84.84% and a negative net margin of 46.59%.

Shares of NASDAQ:SIBN traded down $0.19 during mid-day trading on Tuesday, reaching $18.24. The company had a trading volume of 1,213 shares, compared to its average volume of 107,333. SI-Bone has a one year low of $14.08 and a one year high of $23.03. The firm has a market cap of $454.67 million and a price-to-earnings ratio of -25.94. The company has a current ratio of 12.00, a quick ratio of 11.55 and a debt-to-equity ratio of 0.50. The company’s 50-day moving average price is $17.25 and its 200-day moving average price is $18.00.

In related news, major shareholder Skyline Venture Partners V. Lp sold 47,576 shares of SI-Bone stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $20.15, for a total value of $958,656.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Skyline Venture Partners V. Lp sold 152,424 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $18.40, for a total transaction of $2,804,601.60. The disclosure for this sale can be found here. Insiders sold a total of 383,524 shares of company stock valued at $7,185,937 over the last quarter. 38.80% of the stock is owned by company insiders.

Separately, ValuEngine cut shares of SI-Bone from a “buy” rating to a “hold” rating in a report on Monday, November 4th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $24.75.

About SI-Bone

SI-BONE, Inc, a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.

Featured Article: Asset Allocation Models, Which is Right For You?

Earnings History for SI-Bone (NASDAQ:SIBN)

Receive News & Ratings for SI-Bone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-Bone and related companies with's FREE daily email newsletter.